Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Isis Makes Quick Gain From Ortho-McNeil Pact, Enters Phase I For Novel Diabetes Candidate

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm also will present positive Phase II data on novel small molecule targeting apolipoprotein B-100 for treatment of familial hypercholesterolemia later this week.

You may also be interested in...



Isis Lipid-Lowering Candidate Named Mipomersen; Firm Projects Smaller Loss

Firm revises net operating loss guidance downward by roughly $20 million.

Isis Lipid-Lowering Candidate Named Mipomersen; Firm Projects Smaller Loss

Firm revises net operating loss guidance downward by roughly $20 million.

Isis Lipid-Lowering Drug Shows Benefit In Phase II For Familial Hypercholesterolemia

Isis 301012 shows treatment benefit as an add-on therapy to statins and other drugs.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS065231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By